Form 4: Cogent Biosciences Director Receives Stock Options

Karen Jean Ferrante, a Director at Cogent Biosciences, Inc., was granted stock options valued at $38.48 per share, with 627 options awarded on July 1, 2026.

Summary

• Karen Jean Ferrante, a Director at Cogent Biosciences, Inc. (COGT), received a grant of stock options on July 1, 2026.
• The grant consists of 627 stock options, each with an exercise price of $38.48.
• These options were issued as part of the Issuer's non-employee director compensation plan, where the director elected to receive shares in lieu of cash compensation.
• The number of options granted was calculated by dividing the cash compensation otherwise payable for the quarter by the Black-Scholes value of a single option on the grant date.
• The options are exercisable from July 1, 2026, to July 1, 2036.
• Following this transaction, Ms. Ferrante beneficially owns 627 shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine director compensation and does not provide insights into the company's operational or financial performance.

Positives

• Director compensation aligns with equity ownership through stock options, potentially incentivizing long-term value creation.
• The grant is part of a structured non-employee director compensation plan, indicating established governance practices.
• The exercise price of $38.48 suggests a valuation at the time of grant that may reflect market conditions or company performance.

Negatives

• The filing does not provide details on the company's financial performance or strategic updates, making it difficult to assess the broader context of this compensation award.
• The value of the stock options is contingent on future stock price performance, introducing inherent risk for the recipient.

Risks

• The value of the stock options is subject to market volatility and the company's future performance.
• If the company's stock price does not exceed the exercise price of $38.48, the options may expire worthless.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction. The future outlook for the stock options is dependent on the company's stock price performance.

Management Comments

• The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan.
• The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with shareholder interests. However, the specific value and impact of this grant are isolated to director compensation and do not reflect broader company performance metrics.

Corporate Governance

Related Party Transactions

• The transaction involves Karen Jean Ferrante, a Director, receiving stock options as compensation, which is a related-party transaction governed by the company's compensation plan.

Stakeholder Impact

• Shareholders: The issuance of options dilutes existing share ownership slightly, but also aligns director incentives with long-term shareholder value.
• Employees: No direct impact mentioned.
• Management: The compensation structure for directors is confirmed.
• Creditors: No direct impact mentioned.

Next Steps

• The stock options are exercisable between July 1, 2026, and July 1, 2036.
• The reporting person may choose to exercise these options if the stock price exceeds the exercise price of $38.48.

Key Dates

Keywords

Cogent Biosciences, COGT, Form 4, Stock Options, Director Compensation, Beneficial Ownership, SEC Filing, Equity Award